HLS Therapeutics Inc is facing a downturn as its stock slips 0.71% in the latest trading session, raising concerns among investors.
In a disappointing turn of events, HLS Therapeutics Inc (HLS.TO) saw its stock price decline by 0.71% in the last trading session, closing at CA$4.22. This drop reflects ongoing challenges for the company, which is still navigating a complex market landscape without any recent positive news to bolster investor confidence.
Investor takeaway: Investors should remain cautious as HLS Therapeutics grapples with its financial performance and market perception. The lack of recent positive developments may contribute to ongoing volatility.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.85M
52W high
$5.76
52W low
$4.00
1W change
-3.06%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.29
+76.9% Upside
Current Price
C$4.12
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
27.8%
Annualized
90-Day Vol
22.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.88 | C$3.53 – C$4.27 |
| 60 trading days | C$3.66 | C$3.19 – C$4.19 |
| 90 trading days | C$3.45 | C$2.92 – C$4.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Market Cap: CA$137.9 million
With a market cap of CA$137.9 million, HLS Therapeutics is under scrutiny as it continues to report negative profit margins, highlighting the need for strategic improvements.
Bull case
Despite the current downturn, HLS Therapeutics has previously reported growth in revenue and cash from operations. This suggests there’s potential for recovery if market conditions improve.
Bear case
The persistent losses and lack of significant news may signal deeper issues within the company, making it a risky investment at this time.
Advertisement
Current Market Performance
HLS Therapeutics Inc's stock has taken a hit, dropping 0.71% in the latest trading session. This decline comes at a time when the company is facing scrutiny over its financial performance and market strategy. Investors should be aware of the company's current standing as it navigates through a challenging environment.
Financial Health Overview
With a market cap of CA$137.9 million and a troubling profit margin of -18.46%, HLS Therapeutics is under pressure to improve its financial health. The recent lack of positive news and developments further complicates the outlook for investors considering entering or holding onto their positions in HLS.TO.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
